

#4

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thomas S.Y. KO

Group Art Unit: 1615

Appln. No.: 09/717,088

Examiner: Unknown

Filed: November 22, 2000

Confirmation No.: 1770

For: NOVEL COMPOSITIONS AND METHODS

SUBMISSION OF PRIORITY DOCUMENT


Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

Applicant submits herewith the certified copy of the original priority document (i.e., PQ-4190) on which claim to priority is made under 35 U.S.C. § 119.

The Examiner is respectfully requested to acknowledge receipt of said priority document.

Respectfully submitted,


Gordon Kit
Registration No. 30,764

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
(202) 293-7060

Date: April 12, 2001

Our Ref: 732740/PS

P/00/009
Regulation 3:2

AUSTRALIA

Patents Act 1990

PROVISIONAL SPECIFICATION

Applicant(s): Thomas Sai Ying Ko
4 Licence Road
Belgrave South
Victoria 3160
AUSTRALIA

Address for Service: DAVIES COLLISON CAVE
Patent & Trade Mark Attorneys
Level 10, 10 Barrack Street
SYDNEY NSW 2000

Invention Title: **Novel compositions and methods**

The invention is described in the following statement:

NOVEL COMPOSITIONS AND METHODS

FIELD OF THE INVENTION

The present invention relates to a non-aerosol spray-on skin patch composition and to
5 methods of using it in improving wound healing, and/or administering a physiologically
active ingredient to a patient. The invention also relates to a spray on skin patch drug
delivery system. Other aspects of the invention will become apparent from the description
that follows.

10 BACKGROUND OF THE INVENTION

Although there are several skin patch compositions available on the market, which can be
used for forming a protective film over a wound, they are associated with a number of
problems. The spray-on skin patches presently known basically take the form of a water
insoluble polymer dissolved in an organic solvent, with an appropriate propellant that will
15 allow it to be applied in an aerosol form. A significant disadvantage with such compositions
is that after being applied to the skin and being left to dry a non-porous film structure is
formed that prevents the passage across it of gasses or moisture. The failure to allow
moisture to move away from the wound results in excess moisture being trapped beneath the
film surface causing depredation of the wound, and the possibility of infection.

20

It is also problematic that due to delivery via an aerosol means with the aid of a propellant,
the spray-on skin patch is applied at a high pressure and can cause pain or discomfort to the
patient when applied to a wound area. It has previously not been thought possible to
eliminate the propellant from such compositions in order that the composition can be
25 administered under lower pressure, the reason being that it was generally believed the
presence of propellant was essential to prevent the clogging of the spraying nozzle through
which the composition is applied.

Use of known spray-on skin patch composition has also been demonstrated in the past to
30 allow the growth of microorganisms beneath the film covering that can lead to wound
infection as indicated above.

The prevention or treatment of local or topical disease states or conditions of the skin has
traditionally used simple non-occlusive delivery systems. These drug delivery systems
35 usually include a volatile and/or non-volatile medium where a composition of the drug and
medium is topically applied to the skin, in the vicinity of or directly on the area of skin to be

treated. These delivery systems usually take the form of emulsion, creams, ointments, foams, gels, liquids, sprays and aerosols. Such delivery systems are generally used to treat skin inflammations, fungal and bacterial topical infection, soft-tissue contusions, parasites and topical analgesia. The limitation with this type of delivery system is that systemic drugs
5 are generally not suitable for this type of administration, due to various factors possibly including the short interval of application. Some major problems with the current state of the art relate to a lack of efficacy of systemic drugs because of the low drug flux across the skin, inability to adequately control the rate of drug delivery, or the requirement for a very large application area. Problems with the poor dermal penetration of drugs is that the drug
10 can be easily washed off, or transferred to clothes, other surfaces.

The dermal delivery of drugs may represent one of the oldest form of drug delivery in human history, Resins and animal fats were probably used by humans in early times to treat damage to the skin resulting from injuries and burns. Such substances for local delivery of
15 active substances remained largely unchanged until as late as this century. The concept of transdermal systemic drug delivery was first seriously advocated by Dr Alejandro Zaffaroni, for example, in US patents 3598122 and 3731683 from the early 1970s. Transdermal systemic drug delivery provides an effective method of achieving improved bioavailability for physiologically active substances where the drugs are poorly absorbed by traditional
20 routes of delivery, and/or when oral dosing is poorly tolerated or not possible.

Transdermal formulations are however limited. For example, polar drugs tend to penetrate the skin too slowly. Since most drugs are of a polar nature this limitation is significant, as is the fact that many drugs cause irritation at the site of topical application.

25

One common method known for assisting the rate of penetration of drugs across the skin is to increase the thermodynamic activity of the drug. The thermodynamic activity of a drug is proportional to the concentration of the drug and the selection of the vehicle. According to the laws of thermodynamics, the maximum activity of a drug is related to that of the pure
30 drug crystal.

From the 1970s a principal focus of transdermal systemic drug delivery has been, and remains, on transdermal patch devices. These patch devices are like bandages which are attached to the surface of intact skin for prolonged periods of time to allow a desired
35 systemic delivery of a drug or other physiologically active agent. These transdermal patch devices occlude the skin and trap the drug, together with volatiles and vehicle excipients,

between the skin and an outer impermeable backing membrane. The membrane prevents the evaporation or diffusion of vehicle excipients, volatiles and drug into an environment other than the specific target skin site. The prolonged length of time required for transfer of the drug and excipients from the patch into the skin often results in local skin irritation. The
5 irritation is caused by prolonged contact on the skin by the drug, volatiles, vehicle excipients, or the adhesive used to attach the patch device to the skin. The occlusive nature of the patch device also restricts the natural ability of the skin to "breathe", this being uncomfortable and increasing the risk of irritation. With added problems of complex and costly manufacturing processes for transdermal patch devices there is a need for improved
10 transdermal drug delivery systems which allow ease of administration, simple preparation and comparatively low cost preparation.

The thermodynamic activity of a drug can be increased by employing supersaturated systems which give rise to unusually high thermodynamic potentials (Coldman, *et al*, *J.*
15 *Pharm. Sci.* 58(9):119, 1969). However, topical vehicles relying on supersaturation have the major limitation of formulation instability, both prior to and during application to the skin. As such, they are of limited clinical value within a non-occlusive volatile:non-volatile delivery vehicle, because as soon as the formulation comes into contact with a person's clothing or the like, the drug often precipitates; hence the formulation is no longer
20 supersaturated and any enhanced percutaneous absorption ceases.

Other workers such as Kondo, *et al* (*J. Pharmacobio-Dyn.*, 10:743 1987) who were using supersaturation to achieve enhanced transdermal drug delivery, have relied on the use of anti-nucleating polymers to stabilize the formulation. However, the applied drug
25 formulations stabilized with polymers formed an appreciable surface mass on the skin which remained there over a prolonged duration of many hours, not a few minutes. So, while Kondo advocated the use of a metered spray to deliver these formulations, in reality it would be impossible to obtain a non-occlusive delivery system with a short application time and still maintain a clinically useful transdermal penetration enhancement.

30

It is accordingly an object of the present invention to provide a spray-on skin patch composition that overcomes some of the problems associated with prior art compositions and systems. Other objects of the present invention will become apparent from the following detailed description.

35

SUMMARY OF THE INVENTION

According to one embodiment of the present invention there is provided a non-aerosol spray-on skin patch composition comprising:

- (a) at least one substantially water insoluble film forming agent;
 - (b) at least one film plasticiser agent;
 - 5 (c) at least one water soluble compound; and
 - (d) at least one organic solvent;
- the composition forming a flexible, porous and physiologically compatible skin patch when sprayed onto skin and allowed to dry.
- 10 The composition may also include a physiologically active ingredient or pro-drug thereof for application to a wound site.

According to another embodiment of the invention there is provided a spray patch skin delivery composition comprising:

- 15 (a) at least one substantially water insoluble film forming agent;
 - (b) at least one film plasticiser agent;
 - (c) at least one water soluble compound;
 - (d) at least one organic solvent; and
 - (e) a physiologically active ingredient or a pro-drug thereof ;
- 20 the composition forming a flexible, porous and physiologically compatible skin patch when sprayed onto skin and allowed to dry, and which provides transdermal drug delivery.

According to another aspect of the invention there is provided a spray patch transdermal drug delivery system which comprises at least one physiologically active agent or pro-drug
 25 thereof in a water insoluble, porous, film structure containing drug depots.

According to a still further embodiment of the present invention there is provided a method of improving wound healing or administering a physiologically active ingredient to a patient in need of such treatment comprising applying to a wound or to skin of the patient an
 30 effective amount of a composition as referred to above.

DETAILED DESCRIPTION OF THE INVENTION

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will
 35 be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

By the term "non-aerosol" it is intended to mean that the composition does not comprise a propellant that will serve to deliver it under pressure. By way of example, the composition may conveniently be applied from a pump-pack type of dispensing container that will utilise
5 the pumped influx of air to force the composition out through a spraying nozzle, under relatively low pressure.

There are several aspects to the invention. In one main aspect the skin patch composition is adapted to be sprayed onto a wound, such as for example a cut, sore, abrasion, burn or other
10 affected part of the skin. In another aspect, a spray patch skin delivery composition is adapted to be applied to normal skin as a means of delivering to or through the skin (transdermally) of the patient a physiologically active ingredient such as systemically active drug, or prodrug thereof. In such cases the spray-on skin patch composition will preferably be delivered/administered in a metered dose.

15

In a first aspect of the invention the composition comprises at least one substantially water insoluble film forming agent, at least one film plasticiser agent, at least one water soluble compound and at least one organic solvent. The ingredients should of course be physiologically compatible and when combined, administered to the skin and allowed to dry
20 the composition forming a flexible, and physiologically compatible porous, skin patch or skin covering film which degrades over time.

The film forming agents that may be used in the present invention include acrylic acid and its derivatives, polyacrylic and its derivatives such as polybutylmethacrylate and
25 polymethacrylic acid, ascorbyl palmitate, carbomer, carnauba wax, cellulose derivatives such as cellulose acetate phthalates, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose and related compounds, hydroxypropyl methylcellulose phthalate, hypromellose phthalate, crospovidone and derivatives/related compounds, cetyl alcohol and derivatives, microcrystalline wax, poloxamer, polyethylene
30 glycol, polyurethane, polyvinyl acetate, polyvinyl acetate phthalate, polyvinyl alcohol, povidone, silicone rubber and derivatives, shellac, and triglycerides derivatives. These film forming agents are organic solvent soluble, for example, in organic solvents which are dermatological compatible solvents used in dermatological, pharmaceutical and veterinary applications.

35

It is also possible for a number of substantially water insoluble film forming agents to be included within the composition, which when combined and applied to the skin will likewise form a flexible skin patch.

- 5 The composition should include at least one film plasticiser agent that will serve to soften the polymer film formed by the film forming agent and to ensure that it is sufficiently flexible that it can move with the skin on the area to which it is applied without cracking and peeling (at least during the intended lifespan of the skin patch). Examples of suitable film plasticiser agents include polybutylphthalate, benzyl benzoate, dibutyl sebacate,
10 dimethyl phthalate, dibutyl phthalate, triacetin, glycol and derivatives thereof.

An important aspect of the present invention is that the skin patch formed by use of the composition is porous. This porosity is achieved by including within the composition at least one water soluble compound that will be integrated within the polymer film when
15 applied to the skin. Without limiting the invention, it is believed that the presence of a water soluble compound will, when the film comes into contact with moisture, cause molecules of this compound to leach out of the film, resulting in the forming of windows or pores within the film itself. These pores will allow the passage of gases and water vapour through the skin patch film. In a preferred embodiment of the invention the water soluble compound
20 also has another role within the composition, such as for example as a physiologically active ingredient. Examples of physiologically active ingredients that are also water soluble include antimicrobial quaternary ammonium compounds such as for example cetrimide. Compounds such as these will integrate evenly within the film and act immediately on bacteria associated with the effected skin area covered by the film, leaving a multiplicity of
25 windows or pores within the film, allowing the skin beneath to breathe and perspire, and at the same time preventing the trapping of anaerobic bacteria beneath the film. Quaternary ammonium compounds such as cetrimide are advantageous because they have surfactant action which may assist in binding the film onto the skin to which it is applied. Quaternary ammonium compounds such as cetrimide may also assist to soften and maintain the softness
30 of blood clots with which it will come into contact. This action helps to prevent scabbing of a wound, cut or abrasion, thus facilitating the antimicrobial effects.

Other examples of water soluble compounds that can be incorporated within the composition to aid in formation of pores within the skin patch are antifungal agents such as acrisorcin,
35 amorolfine, amphotericin, azoles derivatives and related compounds (bifonazole, butoconazole nitrate, chlormidazole, clotrimazole, croconazole, econazole, enilconazole,

fenticonazole, fluconazole, flutrimazole, isoconazole, itraconazole, ketoconazole, lanoconazole, miconazole, omoconazole, saperconazole, sertaconazole, sulconazole, terconazole, tioconazole) benzoyl disulphide, bromochlorosalicylanilide, buclosamide, butenafine, candicidicaprylic acid, chlorphenesin, ciclopirox olamine, cilofungin, fenticlor, flucytosine, criseofulvin, hachimycin, haloprogin, hamycin, hydroxystilbamidine isethionate, loflucarban, mepartricin, natamycin, nifuroxime, p-nitrophenol, nystatin, pentamycin, propionic acid, protiofate, pyrrolnitrin, sulbentine, terbinafine, tolciolate, tolnaftate, triacetin, undecenoic acid. Water soluble agents are not limited to antimicrobial agents or antifungal agents. Skin conditioners such as ethoxylated lanoline, alcohols (such as C₄ to C₈ alcohols, for example, methanol, ethanol, propanol or isopropanol), and glycerin may be used. Any material that has good solubility in water and slight solubility in volatile organic solvents such as C₄ to C₈ alcohols (for example, methanol, ethanol, propanol or isopropanol), acetone, ethyl acetate, dimethyl ether and other polar solvents may be used.

In order to aid application of the skin patch composition by spraying, the composition will include at least one volatile organic solvent. By way of example only, one or more solvents may be selected from acetone, ethyl acetate and isopropanol. These solvents are preferred as they may offer some bactericide activity. Other solvents that may be adopted include: alcohols such as benzyl alcohol, ethanol, methanol, butanol, isobutanol, diacetone alcohol; chlorinated hydrocarbons such as methylene chloride, carbon tetrachloride, trichloroethylene, chloroethene SM; esters such as methyl acetate, ethyl acetate, n-propyl acetate, n-butyl acetate, isobutyl acetate, amyl acetate, 2-thyl hexyl acetate, duPont DBE, Exxate 500, 700, 900; glycol and ether/ester derivatives, ethylene glycol, PM acetate, butyl celluosolve, Carbitol acetate, butyl Carbitol acetate, Ektapro EEP; hydrocarbons such as toluene, cyclohexane, VM&P naphtha, mineral spirits, Aromatic 100, Aromatic 150, ketones such as acetones, methyl ethyl ketone; or dimethyl ether. These solvents are volatile and, in general, in levels used in dermatological preparations do not cause substantial irritation to the skin. On application to the skin the solvents rapidly volatilize. A small amount of a non-volatile solvent (for example, less than 2%v/v of total solvent) may be included.

30

The spray-on skin patch composition having wound treatment application may optionally include one or more physiologically active ingredients, or prodrugs thereof, that may for example be one or more of, or a combination of the following: rapidly-acting antimicrobials (such as cetrimide), long-acting antimicrobials, such as benzyl benzoate, dibutyl sebacate, dimethyl phthalate, dibutyl phthalate, triacetin, glycol and derivatives, corticosteroids, pain relieving agents, compounds having antiinflammatory activity and biologically active

peptides or proteins. This list of active agents is not intended to be limiting upon the nature of physiologically active ingredients that can be incorporated within such compositions as any agents that are compatible with the other components of the composition and which can be administered effectively via spraying onto the skin are considered to fall within this aspect. Details of physiologically active ingredient which may be used in this aspect are set out below in relation to the spray patch skin delivery composition aspect of the invention.

By the terms "rapidly-acting" and "long-acting" antimicrobials it is envisaged that short-acting antimicrobials will effect an anti-microbial activity at the site of application for a period of between about one and about four hours, whereas long-acting antimicrobials will demonstrate activity over a period of from about four hours to about forty eight hours. Activity can be measured by methods routine in the art, that involve taking a swab from a wound site and monitoring microorganism proliferation and viability following exposure to the anti-microbial concerned.

15

Where the water soluble component of the composition is a physiologically active ingredient, the optional one or more physiologically active ingredient may be the same or different.

20 In accordance with another aspect of the invention there is provided a spray patch skin delivery composition comprising:

- (a) at least one substantially water insoluble film forming agent;
 - (b) at least one film plasticiser agent;
 - (c) at least one water soluble compound;
 - 25 (d) at least one organic solvent; and
 - (e) a physiologically active ingredient or a prodrug thereof ;
- the composition forming a flexible, porous and physiologically compatible skin patch when sprayed onto skin and allowed to dry, and which provides transdermal drug delivery.

30 The physiologically active agent or prodrug thereof which may be used in this aspect includes any locally or systemically active agents which are compatible with the porous film of the invention. These agents may be delivered transdermally through the skin without the need for dermal penetration enhancers (which may cause skin irritation or sensitivity). Examples of physiologically active agents or prodrugs thereof include, one or more
35 conveniently classified below by therapeutic class.

Alimentary System

Antidiarrhoeals such as diphenoxylate, loperamide and hyoscyamine.

Cardiovascular system

5 Antihypertensives such as hydralazine, minoxidil, captopril, enalapril, clonidine, prazosin, debrisoquine, diazoxide, guanethidine, methyl dopa, reserpine, trimetaphan.

Calcium channel blockers such as diltiazem, felodipine, amlodipine, nitrendipine, nifedipine and verapamil.

10 Antiarrhythmics such as amiodarone, flecainide, disopyramide, procainamide, mexiletene and quinidine.

Antiangina agents such as glyceryl trinitrate, erythritol tetranitrate, pentaerythritol tetranitrate, mannitol hexanitrate, perhexilene, isosorbide dinitrate and nicorandil.

Beta-adrenergic blocking agents such as alprenolol, atenolol, bupranolol, carteolol, labetalol, metoprolol, nadolol, nadoxolol, oxprenolol, pindolol, propranolol, sotalol, timolol and
15 timolol maleate.

Cardiotonic glycosides such as digoxin and other cardiac glycosides and theophylline derivatives.

Adrenergic stimulants such as adrenaline, ephedrine, fenoterol, isoprenaline, orciprenaline, rimeterol, salbutamol, salmeterol, terbutaline, dobutamine, phenylephrine,
20 phenylpropanolamine, pseudoephedrine and dopamine. Vasodilators such as cyclandelate, isoxsuprine, papaverine, dipyridamol, isosorbide dinitrate, phentolamine, nicotinic alcohol, co-dergocrine, nicotinic acid, glyceryl trinitrate, pentaerythritol tetranitrate and xanthinol. Antimigraine preparations such as ergotamine, dihydroergotamine, methysergide, pizotifen and sumatriptan.

25

Drugs affecting blood and haemopoietic tissues.

Anticoagulants and thrombolytic agents such as warfarin, dicoumarol, low molecular weight heparins such as enoxaparin; plasminogen activators such as streptokinase and its active derivatives, t-pA and its derivatives and the like.

30 Haemostatic agents such as aprotinin, tranexamic acid and protamine.

Central nervous system

Analgesics, antipyretics including the opioid analgesics such as buprenorphine, dextromoramide, dextropropoxyphene, fentanyl, alfentanil, sufentanil, hydromorphone,
35 methadone, morphine, oxycodone, papaveretum, pentazocine, pethidine, phenoperidine,

codeine and dihydrocodeine. Others include acetylsalicylic acid (aspirin), paracetamol, and phenazone.

Hypnotics and sedatives such as the barbiturates, amylobarbitone, butobarbitone and pentobarbitone and other hypnotics and sedatives such as choral hydrate, chlormethiazole,
5 hydroxyzine and meprobamate.

Antianxiety agents such as the benzodiazepines, alprazolam, bromazepam, chlordiazepoxide, clobazam, chlorazepate, diazepam, flunitrazepam, flurazepam, lorazepam, nitrazepam, oxazepam, temazepam and triazolam.

Neuroleptic and antipsychotic drugs such as the phenothiazines, chlorpromazine,
10 fluphenazine, pericyazine, perphenazine, promazine, thiopropazate, thioridazine and trifluoperazine and the butyrophenones, droperidol and haloperidol and the other antipsychotic drugs such as pimozide, thiothixene and lithium.

Antidepressants such as the tricyclic antidepressants amitriptyline, clomipramine, desipramine, dothiepin, doxepin, imipramine, nortriptyline, opipramol, protriptyline and
15 trimipramine and the tetracyclic antidepressants such as mianserin and the monoamine oxidase inhibitors such as isocarboxazid, phenelzine, tranlycypromine and moclobemide and selective serotonin re-uptake inhibitors such as fluoxetine, paroxetine, citalopram, fluvoxamine and sertraline.

CNS stimulants such as caffeine.

20 Antialzheimer's agents such as tacrine.

Antiparkinson agents such as amantadine, benserazide, carbidopa, levodopa, bentsropine, biperiden, benhexol, procyclidine and dopamine-2 agonists such as S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0923).

Anticonvulsants such as phenytoin, valproic acid, primidone, phenobarbitone,
25 methylphenobarbitone and carbamazepine, ethosuximide, methsuximide, phensuximide, sulthiame and clonazepam.

Antiemetics, antinauseants such as the phenothiazines, prochlorperazine, thiethylperazine and 5HT-3 receptor antagonists such as ondansetron and granisetron and others such as dimenhydrinate, diphenhydramine, metoclopramide, domperidone, hyoscine, hyoscine
30 hydrobromide, hyoscine hydrochloride, clebopride and brompride.

Musculoskeletal system

Non-steroidal antiinflammatory agents including their racemic mixtures or individual enantiomers where applicable, such as ibuprofen, flurbiprofen, ketoprofen, aclofenac,
35 diclofenac, aloxiprin, apoxen, aspirin, diflunisal, fenoprofen, indomethacin, mefenamic

acid, naproxen, phenylbutazone, piroxicam, salicylamide, salicylic acid, sulindac, desoxysulindac, tenoxicam, tramadol and ketoralac.

Additional non-steroidal antiinflammatory agents which can be formulated in combination
 5 with the dermal penetration enhancers include salicylamide, salicylic acid, flufenisal, salsalate, triethanolamine salicylate, aminopyrine, antipyrine, oxyphenbutazone, apazone, cintazone, flufenamic acid, clonixeril, clonixin, meclofenamic acid, flunixin, colchicine, demecolcine, allopurinol, oxypurinol, benzydamine hydrochloride, dimefadane, indoxole, intrazole, mibane hydrochloride, paranylene hydrochloride, tetradamine, benzindopyrine
 10 hydrochloride, fluprofen, ibufenac, naproxol, fenbufen, cinchophen, diflumidone sodium, fenamole, flutiazin, metazamide, letimide hydrochloride, nexeridine hydrochloride, octazamide, molinazole, neocinchophen, nimazole, proxazole citrate, tesicam, tesimide, tolmetin, and triflumidale.

Antirheumatoid agents such as penicillamine, aurothioglucose, sodium aurothiomalate,
 15 methotrexate and auranofin.

Muscle relaxants such as baclofen, diazepam, cyclobenzaprine hydrochloride, dantrolene, methocarbamol, orphenadrine and quinine.

Agents used in gout and hyperuricaemia such as allopurinol, colchicine, probenecid and sulphapyrazone.

20

Hormones and steroids

Oestrogens such as oestradiol, oestriol, oestrone, ethinyloestradiol, mestranol, stilboestrol, dienoestrol, epioestriol, estropipate and zeranol.

Progesterone and other progestagens such as allyloestrenol, dydrogesterone, lynoestrenol,
 25 norgestrel, norethindrel, norethisterone, norethisterone acetate, gestodene, levonorgestrel, medroxyprogesterone and megestrol.

Antiandrogens such as cyproterone acetate and danazol.

Antioestrogens such as tamoxifen and epitiostanol and the aromatase inhibitors, exemestane and 4-hydroxy-androstenedione and its derivatives.

30 Androgens and anabolic agents such as testosterone, methyltestosterone, clostebol acetate, drostanolone, furazabol, nandrolone oxandrolone, stanozolol, trenbolone acetate, dihydrotestosterone, 17-alpha-methyl-19-nortestosterone and fluoxymesterone

5-alpha reductase inhibitors such as finasteride, turosteride, LY-191704 and MK-306.

Corticosteroids such as betamethasone, betamethasone valerate, cortisone, dexamethasone,
 35 dexamethasone 21-phosphate, fludrocortisone, flumethasone, fluocinonide, fluocinonide desonide, fluocinolone, fluocinolone acetonide, fluocortolone, halcinonide, halopredone,

hydrocortisone, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, hydrocortisone 21-acetate methylprednisolone, prednisolone, prednisolone 21-phosphate, prednisone, triamcinolone, triamcinolone acetonide.

- 5 Further examples of steroidal antiinflammatory agents for use in the instant compositions include cortodoxone, fluoracetone, fludrocortisone, difluorsone diacetate, flurandrenolone acetone, medrysone, amcinafel, amcinafide, betamethasone and its other esters, chloroprednisone, clor cortelone, descinone, desonide, dichlorisone, difluprednate, flucoronide, flumethasone, flumsolide, flucortolone, fluoromethalone, fluperolone,
 - 10 fluprednisolone, meprednisone, methylmeprednisolone, paramethasone, cortisone acetate, hydrocortisone cyclopentylpropionate, cortodoxone, flucetone, fludrocortisone acetate, flurandrenolone acetone, medrysone, amcinafel, amcinafide, betamethasone, betamethasone benzoate, chloroprednisone acetate, clor cortolone acetate, descinone acetone, desoximetasone, dichlorisone acetate, difluprednate, flucoronide, flumethasone
 - 15 pivalate, flunisolid acetate, fluperolone acetate, fluprednisolone valerate, paramethasone acetate, prednisolamate, prednival, triamcinolone hexacetone, cortivazol, formocortal and nivazol. Pituitary hormones and their active derivatives or analogs such as corticotrophin, thyrotropin, follicle stimulating hormone (FSH), luteinising hormone (LH) and gonadotrophin releasing hormone (GnRH).
 - 20 Hypoglycaemic agents such as insulin, chlorpropamide, glibenclamide, gliclazide, glipizide, tolazamide, tolbutamide and metformin.
- Thyroid hormones such as calcitonin, thyroxine and liothyronine and antithyroid agents such as carbimazole and propylthiouracil.
- Other miscellaneous hormone agents such as octreotide.
- 25 Pituitary inhibitors such as bromocriptine.
- Ovulation inducers such as clomiphene.

Genitourinary system

- Diuretics such as the thiazides, related diuretics and loop diuretics, bendrofluazide,
- 30 chlorothiazide, chlorthalidone, dopamine, cyclopenthiazide, hydrochlorothiazide, indapamide, mefruside, meycholthiazide, metolazone, quinethazone, bumetanide, ethacrynic acid and frusemide and potassium sparing diuretics, spironolactone, amiloride and triamterene.
- Antidiuretics such as desmopressin, lyppressin and vasopressin including their active
- 35 derivatives or analogs.

Obstetric drugs including agents acting on the uterus such as ergometrine, oxytocin and gemeprost.

Prostaglandins such as alprostadil (PGE1), prostacyclin (PGI2), dinoprost (prostaglandin F2-alpha) and misoprostol.

5

Antimicrobials

Antimicrobials including the cephalosporins such as cephalexin, cefoxitin and cephalothin. Penicillins such as amoxycillin, amoxycillin with clavulanic acid, ampicillin, bacampicillin, benzathine penicillin, benzylpenicillin, carbenicillin, cloxacillin, methicillin, phenethicillin,

10 phenoxymethylpenicillin, flueloxacillin, mezlocillin, piperacillin, ticarcillin and azlocillin.

Tetracyclines such as minocycline, chlortetracycline, tetracycline, demeclocycline, doxycycline, methacycline and oxytetracycline and other tetracycline-type antibiotics.

Aminoglycosides such as amikacin, gentamicin, kanamycin, neomycin, netilmicin and tobramycin.

15 Antifungals such as amorolfine, isoconazole, clotrimazole, econazole, miconazole, nystatin, terbinafine, bifonazole, amphotericin, griseofulvin, ketoconazole, fluconazole and flucytosine, salicylic acid, fezatione, ticlatone, tolnaftate, triacetin, zinc, pyrrhione and sodium pyrrhione. Quinolones such as nalidixie acid, cinoxacin, ciprofloxacin, enoxacin and norfloxacin. Sulphonamides such as phthalylsulphthiazole, sulfadoxine, sulphadiazine,

20 sulphamethizole and sulphamethoxazole.

Sulphones such as dapsone.

Other miscellaneous antibiotics such as chloramphenicol, clindamycin, erythromycin, erythromycin ethyl carbonate, erythromycin estolate, erythromycin gluceptate, erythromycin ethylsuccinate, erythromycin lactobionate, roxithromycin, lincomycin, natamycin, 25 nitrofurantoin, spectinomycin, vancomycin, aztreonam, colistin IV, metronidazole, tinidazole, fusidic acid and trimethoprim; 2-thiopyridine N-oxide; halogen compounds, particularly iodine and iodine compounds such as iodine-PVP complex and diiodohydroxyquin; hexachlorophene; chlorhexidine; chloramine compounds; benzoylperoxide.

30 Antituberculosis drugs such as ethambutol, isoniazid, pyrazinamide, rifampicin and clofazimine.

Antimalarials such as primaquine, pyrimethamine, chloroquine, hydroxychloroquine, quinine, mefloquine and halofantrine.

Antiviral agents such as acyclovir and acyclovir prodrugs, famciclovir, zidovudine,

35 didanosine, stavudine, lamivudine, zalcitabine, saquinavir, indinavir, ritonavir, n-docosanol, tromantadine and idoxuridine.

Anthelmintics such as mebendazole, thiabendazole, niclosamide, praziquantel, pyrantel embonate and diethylcarbamazine.

Cytotoxic agents such as plicamycin, cyclophosphamide, dacarbazine, fluorouracil and its prodrugs (described, for example, in *International Journal of Pharmaceutics* 111:223-233 (1994)) methotrexate, procarbazine, 6-mercaptopurine and mucophenolic acid.

Metabolism

Anorectic and weight reducing agents including dexfenfluramine, fenfluramine diethylpropion, mazindol and phentermine.

- 10 Agents used in hypercalcaemia such as calcitriol, dihydrotachysterol and their active derivatives or analogs.

Respiratory system

Antitussives such as ethylmorphine, dextromethorphan and pholcodine.

- 15 Expectorants such as acetylcysteine, bromhexine, emetine, guaiphenesin, ipecacuanha and saponins.

Decongestants such as phenylephrine, phenylpropanolamine and pseudoephedrine.

- 20 Bronchospasm relaxants such as ephedrine, fenoterol, orciprenaline, rimiterol, salbutamol, sodium cromoglycate, cromoglycic acid and its prodrugs (described, for example, in *International Journal of Pharmaceutics* 7:63-75 (1980)), terbutaline, ipratropium bromide, salmeterol and theophylline and theophylline derivatives.

Allergy and immune system

- 25 Antihistamines such as meclozine, cyclizine, chlorcyclizine, hydroxyzine, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dexchlorpheniramine, diphenhydramine, diphenylamine, doxylamine, mebhydrolin, pheniramine, triprolidine, azatadine, diphenylpyraline, methdilazine, terfenadine, astemizole, loratidine and cetirizine.

Local anaesthetics such as bupivacaine, amethocaine, lignocaine, cinchocaine, dibucaine, mepivacaine, prilocaine and etidocaine.

- 30 Stratum corneum lipids, such as ceramides, cholesterol and free fatty acids, for improved skin barrier repair (Man, *et al*, *J. Invest. Dermatol.*, 106(5):1096, 1996).

Neuromuscular blocking agents such as suxamethonium, alcuronium, pancuronium, atracurium, gallamine, tubocurarine and vecuronium.

Smoking cessation agents such as nicotine, bupropion and ibogaine.

- 35 Insecticides and other pesticides which are suitable for local or systemic application.

Dermatological agents, such as vitamins A and E, vitamin E acetate and vitamin E sorbate.

Allergens for desensitization such as house dust mite allergen.

Nutritional agents, such as vitamins, essential amino acids and essential fats.

Keratolytics such as the alpha-hydroxy acids, glycolic acid and salicylic acid.

Psychicenergisers, such as 3-(2-aminopropyl)indole, 3-(2-aminobutyl)indole, and the like.

5

Anti-acne agents such as containing isotretinoin, tretinoin and benzoyl peroxide.

Anti-psoriasis agents such as containing etretinate, cyclosporin and calcipotriol.

Anti-itch agents such as capsaicin and its derivatives such as nonivamide (Tsai, *et al*, *Drug. Dev. Ind. Pharm.*, 20(4):719, (1994)).

- 10 Anticholinergic agents, which are effective for the inhibition of axillary sweating and for the control of prickly heat. The antiperspirant activity of agents such as methatropine nitrate, propantheline bromide, scopolamine, methscopolamine bromide, and the new class of soft antiperspirants, quaternary acyloxymethyl ammonium salts (described, for example, by Bodor *et al*, *J. Med. Chem.*, 23:474 (1980) and also in United Kingdom Specification No
- 15 2010270, published 27 June 1979).

Other physiologically active peptides and proteins, small to medium-sized peptides, for example, vasopressin and human growth hormone.

- The physiologically active agent or a prodrug thereof is preferably present at a concentration
- 20 which is soluble in the delivery system, but after evaporation of solvent may precipitate forming drug depots in the porous film.

- A concentration gradient is believed, without wished to be bound by theory, to be the means through which biologically agents or prodrugs thereof pass through the skin. It is believed
- 25 that the porous nature of the patch or film which forms on the skin provides a depot like effect with foci of highly concentrated biologically active agents. The concentration gradient so formed is believed to force the agent across the skin. A continuous delivery may result. It is also believed that the porous nature of the film, which allows the passage of gases and water vapour, and avoids issues of skin irritation associated with films/patches
- 30 applied to the skin for transdermal application.

- An advantage of the compositions according to the present invention is that they may disintegrate over a period of time so that peeling or scrubbing off of the film may be unnecessary. The time frame of such disintegration is governed by the choice of the film
- 35 forming agent and the degree of interruption within the film that has been caused by addition to the composition of a water soluble compound. By selection of these components the

lifespan of the skin patch can be varied as a design feature of the composition. For example, the patch may disintegrate over say a twenty four or forty eight hour time period.

In another aspect of the invention there is provided a spray patch transdermal drug delivery system which comprises at least one physiologically active agent or pro-drug thereof in a water insoluble, porous, film structure containing drug depots.

The drug delivery system is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human. The device is of low toxicity to, and is exceptionally well tolerated by the dermal surface or mucosal membrane of the animal.

The present invention also provides a method for administering at least one systemic or locally acting physiologically active agent or prodrug thereof to an animal which comprises applying an effective amount of the physiologically active agent in the form of a composition or a drug delivery system according to the present invention.

Preferably the animal is a human but the invention also extends to the treatment of non-human animals, such as companion animals (for example, dogs and cats), domestic animals, for example, cows/cattle, sheep, horses, goats, pigs and the like, and birds.

Surprisingly, the compositions and device of the invention enhances the absorption of active agents and prodrugs thereof through the skin and mucous membranes while avoiding the significant pharmacological disadvantages and toxicities of prior art approaches.

25

In the compositions and drug delivery systems according to the various aspects of the invention a pharmaceutical compounding agent, cosolvent, surfactant, emulsifier, antioxidant, preservative, stabilizer, diluent or a mixture of two or more of said components may be incorporated as is appropriate to the particular route of administration and dosage form. The amount and type of components used should be compatible with the polymer film structure. A cosolvent, or other standard adjuvant such as a surfactant, may be used to maintain a physiologically active agent, or prodrug, thereof in a solution or suspension at the desired concentration.

35 The pharmaceutical compounding agents can include paraffin oils, esters such as isopropyl, myristate, ethanol, silicone oils and vegetable oils. These are preferably used in the range of

greater than 1%. Surfactants such as ethoxylated fatty alcohols, glycerol monostearate, phosphate esters, and other commonly used emulsifiers and surfactants preferably in the range of 0.1% to 1% may be used, as may be preservatives such as hydroxybenzoate esters for preservation of the compound preferably in amounts of 0.01% to 0.5%. Typical
5 cosolvents and adjuvants may be ethyl alcohol, isopropyl alcohol, acetone, dimethyl ether and glycol ethers such as diethylene glycol monoethylether. These may be used in amounts of 1% to 90%.

When a pharmaceutical compounding agent, cosolvent, surfactant, emulsifier, antioxidant,
10 preservative, stabilizer, diluent or a mixture of two or more of said components is used, these must be compatible with the ability of the system to become touch-dry after application.

The non-aerosol spray-on skin patch compositions according to the invention can
15 conveniently be applied by means of a positive displacement metered dose hand pump, preferably having a lock down device that will seal the entry of air into the can. The organic solvents included within the composition will serve to clean the spraying nozzle and prevent build up of polymer film there within. By using the metered dose pump it is possible to deliver a precise amount of film onto the skin, and this in association with knowledge of the
20 concentration of physiologically active ingredients within the composition can serve to ensure that the level of active administered is tightly controlled. Other variables that will need to be considered in the control of active ingredient administration (especially in the situation where the dose application is not metered) include the area of skin contacted with the composition, and the length of time of skin contact. Naturally, it will be well within the
25 capabilities of a skilled physician to determine the effective amount of the physiologically active ingredient that needs to be applied and alter the variables mentioned above in order to ensure the correct level of administration. Factors that would be apparent to a skilled clinician such as the height, weight, age, sex and general state of health of the patient concerned may also need to be considered, in determining the correct dose for a specific
30 patient. For example, dosage ranges may include an active ingredient in the range from about 0.01 ng to 500 mg, such as 0.01 mg to 100 mg, for example 0.1 mg to 75 mg or 1 mg to 300 mg per dose.

In one embodiment the skin delivery composition may comprise a non-aerosol spray-on skin
35 patch composition comprising:

0.01% to 10% w/w of a physiologically active ingredient/s

5% to 15% w/w of polymethacrylic acid

0.5% to 2% w/w of polybutylphthalate

0% to 10% w/w of isopropanol

5 0% to 40% w/w of acetone

ethylacetate up to 100% w/w,

the composition forming a flexible, porous and physiologically compatible skin patch when sprayed onto skin and allowed to dry.

10 Other physiologically acceptable carriers, diluents, solvents or excipients may also be included within the composition, as is well known in the art of pharmaceutical formulation. Details of such materials are provided within *Max Remington's Pharmaceutical Sciences*, 17th Edition, Mack Publishing Co, Easton Pennsylvania, USA, the disclosure of which is included herein in its entirety, by way of reference.

15

Further aspects of the present invention will be explained in the following non-limiting Examples.

EXAMPLES

20

Example 1

A composition is prepared as follows:

a non-aerosol spray-on skin patch composition comprising:

0.05% w/w of Centrimide

25 0.07% w/w of Triclosane

0.6% w/w of Chlobutol

10% w/w of polymethacrylic acid

1.2% w/w of polybutylphthalate

4% w/w of isopropanol

30 24% w/w acetone

ethylacetate up to 100% w/w.



The claims defining the invention are as follows:

1. A non-aerosol spray-on skin patch composition comprising:
 - a) at least one substantially water insoluble film forming agent;
 - 5 b) at least one film plasticiser agent;
 - c) at least one water soluble compound; and
 - d) at least one organic solvent;the composition forming a flexible, porous and physiologically compatible skin patch when sprayed onto skin and allowed to dry.
- 10 2. The composition according to claim 1 comprising at least one physiologically active ingredient.
3. The composition according to claim 2 wherein the physiologically active ingredient is
- 15 a water soluble compound.
4. The composition according to either claim 2 or claim 3 wherein the physiologically active ingredient is an antimicrobial.
- 20 5. The composition according to claim 4 wherein the anti-microbial is a rapidly-acting antimicrobial.
6. The composition according to claim 5 wherein the rapidly-acting anti-microbial is a quaternary ammonium compound.
- 25 7. The compound according to claim 6 wherein the quaternary ammonium compound is cetrimide.
8. The compound according to any one of claims 4 to 7 wherein the antimicrobial or a
- 30 further antimicrobial is a long-acting anti-microbial.
9. The compound according to claim 8 wherein the long-acting antimicrobial is Triclosane or Chlorobutanol.
- 35 10. The composition according to any one of claims 2 to 9 wherein the physiologically active ingredient or a further physiologically active ingredient is selected from



nicotine, a quartico steroid, a pain relieving agent, a cardiac dilater, an antiinflammatory and a biologically active peptide or protein.

11. A spray patch skin delivery composition providing:
 - 5 (a) at least one substantially water insoluble film forming agent;
 - (b) at least one film plasticiser agent;
 - (c) at least one water soluble compound;
 - (d) at least one organic solvent; and
 - (e) a physiologically active ingredient or a prodrug thereof ;
- 10 the composition forming a flexible, porous and physiologically compatible skin patch when sprayed onto skin and allowed to dry, and which breaks down or disintegrates over a time period on skin, and which provides transdermal drug delivery.
12. The composition according to any one of claims 1 to 10 wherein the film forming
15 agent is selected from polymethacrylic acid, polybutyl methacrylate and polyacrylic acid.
13. The composition according to any preceding claim wherein the film plasticiser agent is polybutylphthalate.
- 20 14. The composition according to any one of claims 1 to 12 wherein the organic solvent is selected from isopropanol, acetone and ethylacetate.
15. A non-aerosol spray-on skin patch composition comprising:
25 0.01% to 10% w/w of a physiologically active ingredient/s
5% to 15% w/w of polymethacrylic acid
0.5% to 2% w/w of polybutylphthalate
0% to 10% w/w of isopropanol
0% to 40% w/w of acetone
30 ethylacetate up to 100% w/w,
the composition forming a flexible, porous and physiologically compatible skin patch when sprayed onto skin and allowed to dry.
16. The composition according to claim 15 wherein the physiologically active ingredient/s
35 are selected from one or more of rapidly-acting antimicrobials, long-acting

antimicrobials, nicotine, quaternary steroids, pain relieving agents, cardiac dilators, antiinflammatories and biologically active peptides or proteins.

5

17. The composition according to claim 15 comprising:

0.05% w/w of Centrimide

0.07% w/w of Triclosane

0.6% w/w of Chlobutol

10 10% w/w of polymethacrylic acid

1.2% w/w of polybutylphthalate

4% w/w of isopropanol

24% w/w acetone

ethylacetate up to 100% w/w.

15

18. A method of improving wound healing or administering a physiologically active ingredient to a patient in need of such treatment comprising applying to a wound or to skin of the patient an effective amount of a composition according to any one of claims 1 to 19.

20

DATED this 23rd day of November, 1999

25 **Thomas Sai Ying Ko**

By His Patent Attorneys

DAVIES COLLISON CAVE



Creation date: 06-15-2004
Indexing Officer: LHUYNH2 - LINH HUYNH
Team: OIPEBackFileScanning
Dossier: 09717088

Legal Date: 05-07-2001

No.	Doccode	Number of pages
1	CTNF	8
2	892	1

Total number of pages: 9

Remarks:

Order of re-scan issued on